research
A decade of biologic treatment observation in juvenile idiopathic arthritis: Lessons learned from the Dutch ABC Register
- Publication date
- 1 June 2012
- Publisher
- Since 1999, the treatment of juvenile idiopathic arthritis (JIA) has been extended with
a new category of drugs: biologic agents (also known as biologicals or biologic disease
modifying anti-rheumatic drugs). Biologic agents consist of natural proteins, like antibodies
and cytokines, and have been developed to target one or more steps of the immune
response. Elucidation of many of the cellular and molecular mechanisms of the immune
system involved in inflammatory arthritis has resulted in an increasing development of
different biologic agents and, in the future, this number will expand even further.
Tumour necrosis factor (TNF) is a proinflammatory cytokine that plays a central role in
the pathogenesis of juvenile idiopathic arthritis. In systemic disease, interleukin (IL)-1
(a proinflammatory cytokine synthesised by fibroblasts in the synovium and macrophages)
and IL-6 (concentrations of which correlate with fever, disease activity, and
platelet counts) are also thought to be important. If inhibition of these cytokines is not
sufficient, other drugs that aim at T cell blockade and B cell depletion are available. Only
etanercept (TNF-alpha receptor antagonist), adalimumab (anti-TNF-alpha antibody),
abatacept (selective T-cell co-stimulation modulator) and tocilizumab (IL-6 receptor
antibody) have been approved by the European Medicines Agency and the Food and
Drug Administration for the treatment of JIA. Until now, also infliximab (anti-TNF-alpha
antibody), anakinra (IL-1 receptor antagonist), canakinumab (anti-IL-1 antibody) and
rilonacept (IL-1 receptor antagonist), though not approved, are available options or
under investigation for the treatment of JIA.
All of the above mentioned agents have been studied in randomized controlled clinical
trials with inclusion of JIA patients.But after approval and sometimes off-label use in
daily clinical practice, prospective observational studies are crucial to evaluate the longterm
effectiveness and safety in a non-selected patient group. Furthermore, additional
information with regard to the optimal use and the use in specific subgroups of patients
is required. These studies are known as Phase IV post-marketing surveillance studies.
Because of the long-term aspect and the requirements of studying a large population,
such studies have for practical and financial reasons an observational character, as for
example the Dutch national Arthritis and Biologics in Children (ABC) Register.